Atara Biotherapeutics, Inc.
- ATRA
- NASDAQ
- Biotechnology
- T-Cell Immunotherapies
- Off-the-Shelf Cell Therapy
$8.96
Today −2.40%Quote Oct 19, 2026, 08:00 PM UTC
−5.46%over the last month
Max drawdown −17.1%From 1-month high −5.8%3 months +10.7%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Atara Biotherapeutics
Founded in 2012 and headquartered in South San Francisco, California, Atara Biotherapeutics, Inc. is dedicated to pioneering ready-to-use (off-the-shelf) T-cell immunotherapies. Their primary focus in the United States involves creating treatments for patients battling cancer, autoimmune disorders, and viral infections.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
10
Founded
2012
Market value
$89.9M
Quote Oct 19
Analyst target
$13.00
+45.1% from here
Floor
$8.94
0.3% below price
Resistance
$9.36
4.5% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about ATRAPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free